Rishi Sunak announces ‘game-changing’ new drug to slim down the nation
Slimming World consultant shares TOP weight loss tips
A weight loss wonder drug Rishi Sunak describes as a “game changer” will be prescribed to tens of thousands in a bid to ease the nation’s health crisis.
The injection curbs hunger and can help patients lose 15 percent of their body weight.
During a £40million, two-year trial, specialist weight management services will be expanded so more people get prescriptions.
The Prime Minister said it will help those struggling to shed the pounds to live healthier lives, and cut NHS waiting lists by reducing demand for care.
He added: “Obesity puts huge pressure on the NHS. Using the latest drugs to support people to lose weight will be a game-changer by helping tackle dangerous obesity-related health conditions such as high blood pressure, diabetes and cancer.
“It will reduce pressure on hospitals, support people to live healthier and longer lives and help to deliver on my priority to cut NHS waiting lists.”
Watchdog Nice earlier this year recommended semaglutide, more commonly known as Wegovy, for adults with a body mass index of at least 35 and one weight-related health condition such as diabetes or high blood pressure.
However, it is not yet available in the UK due to supply constraints.
Manufacturer Novo Nordisk said in May it was working to make Wegovy available as soon as possible.
Health officials are understood to be in close discussions with the firm to secure supply for the pilot as soon as the drug launches here.
Nice advised that NHS use should be restricted to specialist weight management services, which are largely hospital-based, meaning only around 35,000 people would be able to access it.
The trial will explore how services can be expanded outside of hospitals and GPs could prescribe the drugs, ensuring tens of thousands more can benefit.
Obesity is one of the biggest strains on the NHS and is a leading cause of several severe health conditions such as cardiovascular disease, diabetes and cancer.
Don’t miss…
Aryna Sabalenka accused of ‘making fun’ of Ukraine with ‘disgusting’ behaviour[LATEST]
British Soap Awards stars burst into laughter over EastEnders blunder[LATEST]
Migrant attack risk means French police ‘refusing to intercept small boats'[LATEST]
It is estimated to cost the health service £6.5billion a year. More than one million hospital admissions were linked to the condition in 2019/20.
Latest data shows 12 million adults in the UK are obese, 28 percent of the population in England, while a further 16 million were overweight.
It means that around two-thirds of the adult population are above a healthy weight – defined as having a BMI of 25 or above.
Delivered via a weekly injection, semaglutide targets an area of the brain that regulates appetite and mimics a hormone that curbs hunger. It can be life-changing for patients such as paramedic Alex Guevara. The father-of-three, from Milton Keynes, Buckinghamshire, cut his weight from 20 to 15 stone after receiving the treatment.
Alex, 47, said: “I needed something dramatic to break the cycle and stop me hurtling towards type 2 diabetes, heart disease and stroke. I was also on medication for depression and asthma. I even felt suicidal.” Health Secretary Steve Barclay said this next generation of obesity drugs had great potential when prescribed alongside exercise, diet and behavioural support. He added: “This pilot will help people live longer, healthier lives.”
NHS medical director Professor Sir Stephen Powis said obesity “can have devastating consequences for the nation’s health”.
He added: “This pilot will help determine if these medicines can be used safely and effectively in non-hospital settings as well as with a range of other interventions we have in place.” Experts on Tuesday night said the drug’s wider use could have huge benefits if closely monitored and offered alongside lifestyle advice.
We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info
Professor Kamila Hawthorne, chair of the Royal College of GPs, said the expansion was welcome but must be backed by “sufficient resource and funding to account for the increased workload”.
She added: “Shifting some of this care safely into primary care is worth exploring as it makes sense for patients to access care within the community.
“Any plans to expand availability of semaglutide in primary care must also be done based on evidence of long-term benefit to patients. And sufficient availability of the drug must be ensured ahead of any roll out, so as not to raise patients’ expectations – as there may be many people who need it.”
Professor Naveed Sattar, an expert in metabolic medicine at the University of Glasgow, said: “Anything that helps more people living with obesity gain access to medicines that help them lose weight sustainably could be a major plus to health outcomes.”
Dr Duane Mellor, a registered dietitian and senior lecturer at Aston University, added: “It is really welcome that the government is investing in weight management services for people living with obesity.
“Hopefully this will go beyond focusing only on a drug and will include dietary, lifestyle and psychological support.”
Source: Read Full Article